| Project/Area Number |
11182101
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TANIGUCHI Tadatsugu The University of Tokyo, Graduate School of Medicine, Professor, 大学院医学系研究科, 教授 (50133616)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIDA Eisuke University of Kyoto, Graduate School of Biostudies, Professor, 大学院生命科学研究科, 教授 (60143369)
TSUKITA Shoichiro University of Kyoto, Graduate School of Medicine, Professor, 医学研究科, 教授 (50155347)
NISHIKAWA Shinichi The Institute of Physical and chemical Research, Laboratory for Stem Cell Biology, Group Director, 発生・再生科学総合研究センター, グループディレクター(研究職) (60127115)
MIYAZONO Kohei The University of Tokyo, Graduate School of Medicine, Professor, 大学院医学系研究科, 教授 (90209908)
NAGATA Shigekazu Osaka University, Graduate School of Frontier Biosciences, Professor, 大学院生命機能研究科, 教授 (70114428)
|
|---|
| Project Period (FY) |
1999 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥121,800,000 (Direct Cost: ¥121,800,000)
Fiscal Year 2004: ¥19,500,000 (Direct Cost: ¥19,500,000)
Fiscal Year 2003: ¥20,600,000 (Direct Cost: ¥20,600,000)
Fiscal Year 2002: ¥19,500,000 (Direct Cost: ¥19,500,000)
Fiscal Year 2001: ¥17,300,000 (Direct Cost: ¥17,300,000)
Fiscal Year 2000: ¥43,200,000 (Direct Cost: ¥43,200,000)
Fiscal Year 1999: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | advanced research / cell adhesion / tumore supressor gene / signal transduction / apoptosis / Cytokine / immune response / anticancer agent / がん研究 / 発がん / がん診断 / がん予防 |
|---|
| Research Abstract |
This priority area, termed "Advanced research on cancer", is aimed at seeking cutting-edge cancer research by incorporating new technologies, disciplines and newly developing fields. In the past five years, much of the new insights have been gained about the mechanisms of oncogenic cell signaling and its suppression, particularly on the role of interferons and TGF-β, both of which function as negative regulator of cell growth. It also became possible to visualize behaviors of oncogene products in living cells and this is a new, important step to our understanding of cell transformation. New molecules have also been identified, which regulate cell adhesion and movement, and their functional analyses have been pursued; these include Claudins and WAVEs and these studies offered new insights in infiltration and metastasis of cancer cells. In addition, much progress has been made in understanding the mechanisms of apoptosis of cancerous cells and the clearance of such dying cells. It is particularly worth mentioning that one of the research project in this priority area spawned a new translational research project, that is, identification of HB-EGF as the target of ovarian cancers and application of CRM197, a mutant form of diphtheria toxin that inhibits HB-EGF, for therapy of this form of cancer. Overall, these achievements are represented in over several thousands of published papers, many of which appeared in journals such as Nature. Many collaborations with industries have been in progress with the aim of developing new drugs for cancer.
|
